Sunday, Feb 28, 2021 - 07:45:08
141 results - (0.001 seconds)

effective shot:

    MIAMI (CBSMiami) – An independent FDA advisory board recommends the approval of the country’s third coronavirus vaccine being produced by Johnson & Johnson. Mike Avila is among the more than 200 people participating in the Johnson & Johnson vaccine trial and he’s not sure if he got the placebo or the real shot, but says the effort was well worth it. READ MORE: South Florida House Republicans Vote Against President Bidens $1.9 Trillion Pandemic Relief Package “It’s been such a trying year for everybody. I kind of felt it was my really big one small way of contributing someway. Today, I figured I can do the clinical trial and maybe will get some information that will help so why not do it,” said Avila. READ MORE: Trump A Dominant Force At Conservative Conference In Orlando But FDA did confirm that the Johnson & Johnson vaccine is only 66 percent...
    SAN JOSE (KPIX) — A new milestone in the fight against the pandemic came Friday when the Food and Drug Administration’s advisory committee recommended the approval of Johnson & Johnson’s COVID-19 vaccine for emergency authorization. Gov. Gavin Newsom announced in a news conference on earlier in the day that the state is expected to receive 380,300 doses of the new vaccine next week. His announcement came as vaccine supply shortage continues to be an issue. READ MORE: High School Girl Sues San Mateo County, State of California to Allow Indoor Youth Sports The final approval for the vaccine could come as soon as this weekend. University of California San Francisco professor of epidemiology George Rutherford said the Johnson & Johnson vaccine could be in the arms of Americans as early as Monday. The one-dose vaccine is 85 percent effective in preventing severe disease and 66 percent effective in protecting against...
    A panel of vaccine experts has voted unanimously to recommend authorization of Johnson & Johnson’s COVID-19 shot, setting the vaccine up for the Food and Drug Administration to allow its release within hours. WHAT YOU NEED TO KNOW ABOUT THE JOHNSON & JOHNSON CORONAVIRUS VACCINE HEADED TOWARD APPROVAL The vaccine, developed by Johnson & Johnson-owned Janssen Pharmaceuticals, takes a single shot to provide the full measure of protection from illness due to COVID-19, whereas the Pfizer and Moderna vaccines already in use in the U.S. require two separate shots spaced out three and four weeks, respectively. The J&J vaccine is also much easier to store and transport than other vaccines as it doesn’t require ultracold temperatures to keep it viable for up to three months. While the FDA does not have to act on the panel’s recommendation, it often does. The consensus among vaccine experts Friday...
    Reuters February 26, 2021 0 Comments A panel of expert advisers to the U.S. Food and Drug Administration is expected to recommend authorization of a one-dose COVID-19 vaccine from Johnson & Johnson on Friday, setting the stage for the unleashing of millions more doses across the country next week. After it receives the recommendation, the FDA is likely to authorize the vaccine for emergency use within a day or so, making it the third available in the United States, and the only one that requires just one shot. The panel, consisting of doctors, infectious disease experts and medical researchers, will convene at 9:00am ET (1400 GMT) and vote in favor or against the vaccine’s use several hours later at the end of the meeting. The panel will consider whether the benefits of the vaccine outweigh its risk for use in people aged 18 and older. Officials from the FDA,...
    DUBAI, United Arab Emirates (AP) — Bahrain became the first nation to authorize Johnson & Johnson’s new single-dose coronavirus vaccine for emergency use on Thursday, the government announced, just a day after U.S. regulators concluded the shot offers strong protection against severe COVID-19. The island kingdom off the coast of Saudi Arabia said it would dole out J&J’s shot to the most vulnerable people, including older adults and those with chronic conditions, without specifying when. It was also unclear when doses would be delivered to the country, which already offers vaccines by state-backed Chinese firm Sinopharm, Pfizer-BioNtech and Oxford-AstraZeneca, as well as Russia’s Sputnik V to its roughly 2 million residents. The move makes Bahrain’s health regulatory authority the first in the world to authorize the J&J vaccine for general use. In addition to the U.S., European regulators and the World Health Organization also are considering J&J’s vaccine. Worldwide, the...
    DUBAI, United Arab Emirates (AP) — Bahrain became the first nation to authorize Johnson & Johnson’s new single-dose coronavirus vaccine for emergency use on Thursday, the government announced, just a day after U.S. regulators concluded the shot offers strong protection against severe COVID-19. The island kingdom off the coast of Saudi Arabia said it would dole out J&J’s shot to the most vulnerable people, including older adults and those with chronic conditions, without specifying when. It was also unclear when doses would be delivered to the country, which already offers vaccines by state-backed Chinese firm Sinopharm, Pfizer-BioNtech and Oxford-AstraZeneca, as well as Russia’s Sputnik V to its roughly 2 million residents. The move makes Bahrain’s health regulatory authority the first in the world to authorize the J&J vaccine for general use. In addition to the U.S., European regulators and the World Health Organization also are considering J&J’s vaccine. Worldwide,...
    Going maskless is a key factor in Covid-19 outbreaks at gyms, studies say Venomous spiders discovered at University of Michigan librarys storage area (Bloomberg) -- The shot made by Pfizer Inc. and BioNTech SE was overwhelmingly effective against the virus in a study, confirming earlier reports and prompting experts to say that immunizations can end the pandemic. The two companies will also examine how people respond to a potential third dose of the vaccine. Load Error Hungary reported the biggest jump in cases in two months, making it one of the outliers as infections slow in many parts of the globe. Finland, also seeing a resurgence, is preparing to tighten its lockdown measures. Meanwhile in Asia, vaccination programs are rolling out this week from Hong Kong to South Korea, with Thailand joining the fray in March. A new variant of the coronavirus, containing a mutation that may help...
    A real-world study of Pfizer's COVID-19 vaccine involving more than half a million inoculated people has demonstrated its overwhelming effectiveness after two doses were given, marking a major milestone for the shot. Even after one dose, the vaccine proved effective at preventing serious illness and death.  According to the independently reviewed study out of Israel's Clalit Research Institute, published Wednesday in the New England Journal of Medicine, two doses of the Pfizer/BioNTech shot were 94% effective at cutting symptomatic COVID-19 cases across all age groups.  "The study provides the first large-scale peer-reviewed evaluation of the effectiveness of a COVID-19 vaccine in a nationwide mass-vaccination setting," the institute said in a statement Thursday.  The vast majority of data on coronavirus vaccine efficacy has been the result of controlled lab conditions in clinical trials, but Israel's speedy vaccine rollouts have provided researchers with the first large-scale real-world data. In many ways,...
    The Biden administration anticipates shipping out 3 to 4 million doses of Johnson & Johnson’s single-shot COVID-19 vaccine next week — if the Food and Drug Administration green-lights it for emergency use, officials said Wednesday. “If authorized we are ready to roll out this vaccine without delay,” White House Coronavirus Response Coordinator Jeff Zients said during a virtual press briefing. Zients explained that on Tuesday he updated the nation’s governors on the administration’s plans to distribute Johnson & Johnson’s vaccine if the FDA grants emergency use authorization. “The governors are carefully planning their efforts and getting ready for the possible new vaccine,” said Zients, noting that the distribution approach for the Johnson & Johnson vaccine “will mirror the current allocations process across jurisdictions, pharmacies and community health centers.” The FDA backed Johnson & Johnson’s single-dose coronavirus vaccine as safe and effective earlier Wednesday, ahead of a Friday meeting in...
    Paul Christian Gordon/Zuma Let our journalists help you make sense of the noise: Subscribe to the Mother Jones Daily newsletter and get a recap of news that matters.Johnson & Johnson’s one-shot coronavirus vaccine is highly effective at preventing severe disease and death from COVID-19, the Food and Drug Administration found in analyses published today. An international study found the vaccine’s efficacy rate to be 72 percent in the United States and 64 percent in South Africa, where a more contagious variant is spreading. While these figures are lower than Pfizer’s and Moderna’s efficacy rates, the vaccine greatly reduces the risk of hospitalization and death from COVID-19 and could play a key role in keeping the pandemic at bay. In a clinical trial of 40,000 people, no one who took the vaccine was hospitalized or died of COVID-19 after the vaccine took effect. Plus, the vaccine requires only one shot and...
    The one-dose COVID-19 vaccine made by Johnson & Johnson protects against severe disease and has no serious safety concerns, according to a new analysis published today by the US Food and Drug Administration. The report takes the vaccine one step closer to authorization by the agency, meaning the United States could have a third shot available in a matter of days. The FDA has spent the last three weeks reviewing data submitted by Johnson & Johnson. The company ran its clinical trial in the United States, South Africa, and Latin America. The vaccine was over 80 percent effective at preventing severe cases of COVID-19 in both South Africa and the United States. No one who was 28 days out from their dose of the vaccine was hospitalized with or died from COVID-19. In the United States, the FDA found that the vaccine was 72 percent effective at preventing...
    The Food and Drug Administration reported Wednesday that Johnson & Johnson’s single-dose vaccine to protect against COVID-19 was safe and 72% efficacious in the U.S., setting it up for a quick authorization process in the coming days. The FDA’s 62-page report showed that the single-shot vaccine developed by Johnson & Johnson-owned Janssen Pharmaceutical had an efficacy rate of 72% in its U.S.-based trial and 66% overall across three regions where the shot was tested. The vaccine is also 85% effective overall at preventing hospitalization and 100% effective at preventing death due to COVID-19. The report’s authors also concluded that the shot has a “favorable safety profile with no specific safety concerns identified that would preclude issuance of an [Emergency use authorization].” The FDA’s panel of vaccine experts will meet for an all-day meeting on Friday to determine whether the vaccine should be authorized for public use. The...
    The Food and Drug Administration backed Johnson & Johnson’s single-dose coronavirus vaccine as safe and effective on Wednesday as the agency weighs whether to clear the shot for emergency use. FDA staff affirmed J&J’s finding that the vaccine was 66 percent effective overall at preventing moderate and severe cases of COVID-19. While not as strong as Pfizer and Moderna’s two-dose vaccines, that efficacy rate could still make J&J’s shot a helpful weapon in the battle against the pandemic. New Jersey-based J&J’s clinical trial of nearly 44,000 people also produced no significant safety concerns that would prevent the FDA from granting an emergency use authorization for the vaccine, agency officials said. The FDA released its analysis of the shot before a Friday meeting of its Vaccines and Related Biological Products Advisory Committee, a panel of experts that will recommend whether to clear the J&J vaccine for emergency use. The...
    WASHINGTON (CBS/AP) — Johnson & Johnson’s single-dose vaccine protects against COVID-19, according to an analysis by U.S. regulators Wednesday that sets the stage for a final decision on a new and easier-to-use shot to help tame the pandemic. The Food and Drug Administration’s scientists confirmed that overall the vaccine is about 66% effective at preventing moderate to severe COVID-19. The agency also said J&J’s shot — one that could help speed vaccinations by requiring just one dose instead of two — is safe to use. READ MORE: Pivot The Humpback Whale, Often Seen In Gulf Of Maine, Found Dead On Maryland Coast That’s just one step in the FDA’s evaluation of a third vaccine option for the U.S. On Friday, the agency’s independent advisers will debate if the evidence is strong enough to recommend the long-anticipated shot. Armed with that advice, FDA is expected to make a final decision within...
    Reuters February 24, 2021 0 Comments Johnson & Johnson’s one-shot COVID-19 vaccine appeared safe and effective in trials, U.S. Food and Drug Administration (FDA) staff said in documents published on Wednesday, paving the way for its approval for emergency use. The FDA’s panel of independent experts meets on Friday to decide whether to approve the shot. While it is not bound to follow the advice of its experts, the FDA did so when authorizing the Pfizer Inc and Moderna Inc vaccines. J&J’s vaccine was 66% effective in preventing COVID-19 against multiple variants in a global trial involving nearly 44,000 people, the company said last month. Its effectiveness varied from 72% in the United States to 66% in Latin America and 57% in South Africa, where a new variant has spread, though the vaccine was 85% effective overall in stopping severe cases of the disease. The vaccine was effective in...
    (Reuters) - Johnson & Johnson's one-shot COVID-19 vaccine appeared safe and effective in trials, U.S. Food and Drug Administration (FDA) staff said in documents published on Wednesday, paving the way for its approval for emergency use. The FDA's panel of independent experts meets on Friday to decide whether to approve the shot. While it is not bound to follow the advice of its experts, the FDA did so when authorizing the Pfizer Inc and Moderna Inc vaccines. J&J's vaccine was 66% effective in preventing COVID-19 against multiple variants in a global trial involving nearly 44,000 people, the company said last month. Its effectiveness varied from 72% in the United States to 66% in Latin America and 57% in South Africa, where a new variant has spread, though the vaccine was 85% effective overall in stopping severe cases of the disease. (Reporting by Manas Mishra in Bengaluru; Editing by Bernard Orr)...
    More On: COVID vaccine New York hotel workers seek COVID-19 vaccine in appeal to Cuomo COVID-19 vaccine shipments to states increasing by another million doses MTA will vaccinate one thousand transit workers per week in Brooklyn Ikea stores in Israel offer COVID-19 vaccinations The Food and Drug Administration backed Johnson & Johnson’s single-dose coronavirus vaccine as safe and effective on Wednesday as the agency weighs whether to clear the shot for emergency use. FDA staff affirmed J&J’s finding that the vaccine was 66 percent effective overall at preventing moderate and severe cases of COVID-19. While not as strong as Pfizer and Moderna’s two-dose vaccines, that efficacy rate could still make J&J’s shot a helpful weapon in the battle against the pandemic. New Jersey-based J&J’s clinical trial of nearly 44,000 people also produced no significant safety concerns that would prevent the FDA from granting an emergency use authorization for...
    By Anna Edney | Bloomberg Johnson & Johnson’s Covid-19 vaccine is safe and effective, U.S. regulators said, a key milestone on the path toward giving Americans access to the first such shot to work in a single dose. The vaccine was 72% effective in a U.S. clinical trial, Food and Drug Administration staff wrote in a document summarizing the company’s trial data, confirming findings J&J released earlier this month. There were no Covid-related deaths in the vaccinated group, the staff wrote. Agency officials prepared the document ahead of a meeting Friday where external advisers will make a non-binding recommendation as to whether the vaccine should be authorized. The analysis supported a favorable safety profile with no specific safety concerns identified that would preclude issuance of an EUA. Vaccines from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE were authorized by the FDA in December, just before...
    Johnson & Johnsons one-shot COVID-19 vaccine appeared safe and effective in trials, U.S. Food and Drug Administration (FDA) staff said in documents published on Wednesday, paving the way for its approval for emergency use. The FDAs panel of independent experts meets on Friday to decide whether to approve the shot. While it is not bound to follow the advice of its experts, the FDA did so when authorizing the Pfizer Inc and Moderna Inc vaccines. J&Js vaccine was 66% effective in preventing COVID-19 against multiple variants in a global trial involving nearly 44,000 people, the company said last month. Its effectiveness varied from 72% in the United States to 66% in Latin America and 57% in South Africa, where a new variant has spread, though the vaccine was 85% effective overall in stopping severe cases of the disease. The vaccine was effective in reducing the risk of COVID-19 and preventing...
    AstraZeneca expects to get US emergency authorization for its COVID-19 vaccine in April, the firm's president told lawmakers on Tuesday.  As soon as it gets the Food and Drug Administration's (FDA) greenlight, AstraZeneca will have 30 million doses of the 62 percent effective shot ready to ship to the US, said president of the biopharmaceuticals arm of the company, Dr Ruud Dobber on Tuesday.  He told members of the House of Representatives' Committee on Energy and Commerce that the company could deliver 'up to 50 million' doses by the end of April.  The Trump Administration inked a deal with AstraZeneca for 300 million doses of its Oxford University-designed vaccine.  It has already been authorized by more than 50 countries and the World Health Organization, but mistrust brewed between the pharma giant and US regulators, who placed its large late-stage US trial on a nearly seven-week hold.  Meanwhile, AstraZeneca's easily stored,...
    JERUSALEM (Reuters) - The rate of COVID-19 infections dropped 95.8% among people who received both shots of Pfizer's vaccine, Israel's Health Ministry said on Saturday. The vaccine was also 98% effective in preventing infections that caused fever or breathing problems and 98.9% effective in preventing hospitalizations and death, the ministry said. The findings were based on data collected nationally through Feb. 13 from Israelis who had received their second shot at least two weeks previously. According to the Health Ministry's website, about 1.7 million people had been administered a second shot by Jan. 30, making them eligible to be included. Previous reports from individual health care providers also showed positive results, spurring Israel to remove restrictions on the economy after weeks of lockdown. On Sunday, schools and many stores will be allowed to reopen. The Health Ministry has also rolled out a "Green Pass" app, linked to personal medical files,...
    Jerusalem — The first dose of the Pfizer vaccination is 85% effective against coronavirus infection between two and four weeks after inoculation, according to a study published in the Lancet medical journal. The pharmaceutical giant and its German partner BioNTech, meanwhile, have told the U.S. Food and Drug Administration that their vaccine can be safely stored at standard freezer temperatures, which, if approved by the FDA, could help facilitate faster distribution by negating the need for expensive deep-freeze storage. The Israeli survey was carried out on healthcare workers at the largest hospital in the country, which on December 19 launched a mass vaccination campaign regarded as the world's fastest. Israeli studies have found the Pfizer vaccine to be 95% effective one week after a second jab, while the Lancet report focused on more than 9,000 medical staff at Sheba hospital near Tel Aviv. Some 7,000 of them received the first...
    NEW YORK (WABC) -- A large-scale Israeli study has pointed to the efficacy of the Pfizer-BioNTech vaccine at preventing symptomatic infections with the coronavirus.Clalit, the largest of Israel's four health care providers, released a study Sunday that compared infections in 600,000 Israelis who had received the vaccine compared to 600,000 who were not immunized.The study found a 94% drop in symptomatic infections and a 92% drop in serious cases of the disease among those vaccinated. It said "the efficacy of the vaccine is preserved in every age group," particularly a week after the second dose of the vaccine.The researchers said the preliminary findings of the ongoing research "is aimed at emphasizing to the population that has yet to vaccinate that the vaccine is highly effective and prevents serious illness."Israel launched its COVID-19 vaccine campaign in December. Since then, over a quarter of the population - 2.5 million people - have...
    Russias Medvedev thrashes Pospisil to extend winning streak The CDC Says This Is When Youre Most Likely to Feel Vaccine Side Effects China’s CanSino Covid Vaccine Shows 65.7% Efficacy (Bloomberg) -- CanSino Biologics Inc.’s experimental coronavirus vaccine has an efficacy rate of 65.7% at preventing symptomatic cases based on an analysis from late-stage trials, adding a one-shot candidate to the world’s growing arsenal against Covid-19. © Photographer: Patricia Castellani/AFP/Getty Images View of information and recruitment modules for the application of the candidate phase III vaccines against COVID-19 of the Chinese pharmaceutical company CanSino Biologics. The inoculation co-developed by the Chinese military and the Tianjin-based biotech company proved effective against symptomatic Covid-19, based on a multi-country analysis first posted on Twitter by Faisal Sultan, Pakistan’s health adviser, on Monday. CanSino later forwarded Sultan’s announcement in a statement. The final stage trial included 30,000 participants and was also 90.98% effective in...
    South Africa suspended the start of its AstraZeneca inoculation program over concerns the shot doesn't work nearly as well against the new variant of the coronavirus first discovered in the country. World Health Organization experts were due to meet Monday to discuss the vaccine. A trial showed the vaccine, developed by AstraZeneca and Oxford University, provides only "minimal" protection against mild to moderate COVID-19 infection caused specifically by the variant that has swept through South Africa. The strain, believed to be more easily transmitted but not to cause significantly more serious illness, has also been detected in the U.S., the U.K. and other nations, but is not believed to be the dominant variant in circulation. Oxford scientists have said the small study conducted in South Africa means their vaccine won't likely help to curb the spread of the new variant, but that there's still hope it can reduce the...
    By Derek Francis and Andy Bruce (Reuters) - British drugmaker AstraZeneca said on Saturday its vaccine developed with the University of Oxford appeared to offer only limited protection against mild disease caused by the South African variant of COVID-19, based on early data from a trial. The study from South Africa's University of the Witwatersrand and Oxford University showed the vaccine had significantly reduced efficacy against the South African variant, according to a Financial Times report published earlier in the day. Among coronavirus variants currently most concerning for scientists and public health experts are the so-called British, South African and Brazilian variants, which appear to spread more swiftly than others. "In this small phase I/II trial, early data has shown limited efficacy against mild disease primarily due to the B.1.351 South African variant," an AstraZeneca spokesman said in response to the FT report. The newspaper said none of the...
    PITTSBURGH (KDKA) — Johnson & Johnson has applied for emergency use authorization from the FDA. This third possibility as a choice under EUA would be a welcomed addition when the country’s supply of vaccine is stretched thin. “To have an option with more manufacturers, more vaccine availability is definitely a good thing,” says AHN Infectious Diseases specialist Dr. Nitin Bhanot. This vaccine has some advantages. It’s a single shot and can be shipped and stored at refrigerator temperatures, making it easier to be at a doctor’s office. “You can put it in the fridge for about three months,” says Dr. Bhanot. “The PCPs have it, and they can give it to patients, they walk in, they get a shot.” In contrast to the Pfizer and Moderna versions, this vaccine does not use mRNA. Johnson & Johnson uses a modified common cold virus, an adenovirus, to carry coronavirus spike...
    AURORA, Colo. (CBS4)– Data from studies done in the United Kingdom show the COVID-19 vaccine made by Novavax is roughly 90% effective. That’s great news as the Phase 3 clinical trial of that vaccine in the United States is underway. (credit: CBS) CBS4 Health Specialist Kathy Wash is a volunteer in the U.S. study. She received her second shot on Tuesday, Feb. 2 and this is her experience. The visit started with nurse practitioner Jennelynn asking a few questions and checking vital signs. I told her I had no side effects after my first injection three weeks ago. “We’ll see how you feel after the second injection,” said Jennelynn. She’s optimistic about the Novavax vaccine candidate. “I’m excited to see the United States numbers when we are done with enrollment,” she said. (credit: CBS) That’s because scientists are excited. A U.K. study found the vaccine was 95.6% effective against the...
    Johnson & Johnson executive Dr. Paul Stoffels addressed the efficacy of the coronavirus vaccine compared to others already available to the public, saying it had revealed "complete protection against death and hospitalization." "We have done this study in the height of the pandemic with huge transmission in the presence of several different variants," the chief scientific officer told "America’s Newsroom," citing the variants in Brazil, South America and South Africa.  "What we learned is that the high percent efficacy against severe disease as well as complete protection against death and hospitalization was basically the key finding," he added. Johnson & Johnson on Friday said its single-shot coronavirus vaccine was 72% effective in preventing moderate-to-severe COVID-19 in the U.S, but fell to 66% in a larger trial conducted worldwide. The results stem from a Phase 3 ENSEMBLE clinical trial, which involved 43,783 participants. The shot was found to be 66% effective in preventing moderate-to-severe illness in Latin America,...
    A single shot of Oxford University's coronavirus vaccine blocks nearly eight in 10 people from getting symptomatic illness A single shot of Oxford University's coronavirus vaccine is 76 per cent effective at preventing symptomatic illness and may have a 'substantial effect' on transmission, research suggests.  In a huge boost to the UK's immunisation drive, analysis of the jab trials found the first dose was extremely successful in preventing people from falling ill within the 12-week time window between getting a second dose.  When the second dose is administered after three months, the jab's efficacy is bumped up to 82.4 per cent, according to the study, which has been submitted to The Lancet for publication.   The results, from more than 17,000 trial volunteers, suggest Britain's vaccination gamble to delay its dosing regimen has paid off.  In a bid to get wider vaccine coverage quicker, regulators pivoted from their original plan to give...
    More On: COVID vaccine McDonald’s paying employees to get COVID-19 vaccine Nearly half of US COVID-19 case, vaccination race/ethnicity data is missing Emails show how top Cuomo aide dominates state’s vaccine program Stick a fork in it: Cuomo shoots down expanding vax eligibility to restaurant workers Russia’s COVID-19 vaccine Sputnik V is about 91 percent effective and appears to prevent serious cases of infection, according to a study published Tuesday. The results in the British medical journal The Lancet are from a Phase 3 trial of about 20,000 people in Russia last fall. Concerns over the safety of the two-dose jab mounted after Russia approved Sputnik V in August — ahead of its Western competitors and before the start of large-scale clinical trials. At the time, President Vladimir Putin said one of his daughters had been vaccinated with it even though it had only been tested in several...
    By MARIA CHENG and DARIA LITVINOVA, Associated Press MOSCOW (AP) — Russian scientists say the country's Sputnik V vaccine appears safe and effective against COVID-19, according to early results of an advanced study published in a British medical journal. The news is a boost for the shot that is increasingly being purchased by nations around the world who are desperate to stop the devastation caused by the pandemic. Researchers say based on their trial, which involved about 20,000 people in Russia last fall, the vaccine is about 91% effective and that the shot also appeared to prevent people from becoming severely ill with COVID-19. The study was published online Tuesday in the journal, Lancet. Scientists not linked to the research acknowledged that the speed at which the Russia vaccine was made and rolled out was criticized for “unseemly haste, corner cutting and an absence of transparency.” “But the outcome reported...
    MOSCOW (AP) — Russian scientists say the country’s Sputnik V vaccine appears safe and effective against COVID-19, according to early results of an advanced study published in a British medical journal. The news is a boost for the shot that is increasingly being purchased by nations around the world who are desperate to stop the devastation caused by the pandemic. Researchers say based on their trial, which involved about 20,000 people in Russia last fall, the vaccine is about 91% effective and that the shot also appeared to prevent people from becoming severely ill with COVID-19. The study was published online Tuesday in the journal, Lancet. Scientists not linked to the research acknowledged that the speed at which the Russia vaccine was made and rolled out was criticized for “unseemly haste, corner cutting and an absence of transparency.” “But the outcome reported here is clear,” British scientists...
    More On: COVID vaccine Congressman gets COVID-19 after second vaccine shot Our leaders failed us on COVID, but miracle science brings hope for relief Over 1,000 COVID-19 vaccines ruined after Florida worker turns off fridge A new libel against Israel from Human Rights Watch Pfizer is speeding up research on COVID-19 vaccines because there is a “high possibility” existing shots against the deadly bug won’t be effective in the future. “It’s a very high likelihood that one day that will happen,” Pfizer CEO Albert Bourla said during a panel at the virtual 2021 Davos World Economic Forum. Bourla hopes to cut the time it takes from recognizing a pandemic-scale infectious disease threat to vaccine authorization to 100 days or less, Business Insider reported. That’s one-third the time of the Trump Administration’s Operation Warp Speed. COVID vaccines were produced in record speed thanks to technological advances, major funding efforts and...
    Experts have been looking forward to seeing results from Johnson and Johnson’s COVID-19 vaccine trials for months. The vaccine is a logistical dream compared to the other two authorized in the US. It’s much easier to store, and it requires only one shot instead of the two required by its competitors. The only outstanding question was how well it actually worked. On Friday, they got their answer — it works pretty well. In a 43,783 person trial that spanned the globe, the vaccine was 66 percent effective at preventing moderate to severe COVID-19. Now, 66 percent might seem like a let down compared to the 90-plus percent efficacy from Pfizer/BioNTech and Moderna. But that’s a matter of perspective. Before results of those vaccine trials came out, researchers were hoping for efficacies of between 60 and 70 percent. (By comparison, seasonal flu vaccines are given the thumbs up when they’re...
    SAN FRANCISCO (CBS SF) — Johnson & Johnson says its vaccine will either prevent you from getting COVID, or if you have it, it would be a much milder case. The company plans to get emergency authorization in the U.S. within a week, and supply 100 million doses by June. It’s first one-shot COVID vaccine and is offering the world a potentially new weapon against the mutating virus. Data shows that the vaccine is 72% effective against moderate and severe COVID-19 in the U.S. It’s 85% efficient in preventing serious symptoms in global trials. “In this moment what are we trying to get to, we are trying to get to herd immunity, we are not trying to get to perfection,” said UCSF Infectious Disease Expert Dr. Monica Gandhi. Dr. Gandhi says if she had a choice, she would be okay with getting one-dose of the Johnson & Johnson...
    NEW BRUNSWICK, N.J. -- Johnson & Johnson's long-awaited vaccine appears to protect against COVID-19 with just one shot - not as strong as some two-shot rivals but still potentially helpful for a world in dire need of more doses.J&J said Friday that in the U.S. and seven other countries, the single-shot vaccine was 66% effective overall at preventing moderate to severe illness, and much more protective - 85% - against the most serious symptoms.There was some geographic variation. The vaccine worked better in the U.S. - 72% effective against moderate to severe COVID-19 - compared to 57% in South Africa, where it was up against an easier-to-spread mutated virus."Gambling on one dose was certainly worthwhile," Dr. Mathai Mammen, global research chief for J&J's Janssen Pharmaceutical unit, told The Associated Press.EMBED More News Videos While the push is on to get more of the COVID-19 vaccine, there is some hope on...
    By Frank Jordans and Maria Cheng | Associated Press Regulators authorized AstraZeneca’s coronavirus vaccine for use in adults throughout the European Union on Friday, amid criticism the bloc is not moving fast enough to vaccinate its population. The European Medicines Agency’s expert committee unanimously recommended the vaccine to be used in those 18 and over, though concerns had been raised this week that not enough data exist to prove it works in older people, and some countries indicated they may not give it to the elderly. The shot is the third COVID-19 vaccine given the green light by the European Medicines Agency after ones by Pfizer and Moderna. The EMA’s decision requires final approval from the European Commission, a process that occurred swiftly with the other vaccines. With trials showing about 60% efficacy, the vaccine appears to offer less protection than ones already authorized, but experts have said any vaccine...
    U.S. likely to start COVID-19 vaccination in children by late spring or early summer - Fauci Chibok: Several remaining missing schoolgirls escape from Boko Haram J&J Vaccine Provides Strong Shield Against Severe Covid (Bloomberg) -- Johnson & Johnson’s one-shot vaccine generated strong protection against Covid-19 in a large, late-stage trial, raising hopes that it can rapidly reshape a stumbling immunization campaign. © Photographer: Scott Eells/Bloomberg The Johnson & Johnson logo is arranged for a photograph in New York, U.S. In a study of more than 43,000 people, the vaccine prevented 66% of moderate to severe cases of Covid-19, according to a company statement Friday. And it was particularly effective at stopping severe disease, preventing 85% of severe infections and 100% of hospitalizations and deaths. Load Error “If you can prevent severe disease in a high percentage of individuals, that will alleviate so much of the stress and human...
    Berlin — Regulators authorized AstraZeneca's coronavirus vaccine for use in adults throughout the European Union on Friday, amid criticism the bloc is not moving fast enough to vaccinate its population. The European Medicines Agency (EMA) licensed the vaccine to be used in people 18 and over, though concerns had been raised this week that not enough data exist to prove it works in older people.   The shot is the third COVID-19 vaccine given the greenlight by the European Medicines Agency, after ones made by Pfizer and Moderna. All three have been authorized for all adults.   Many countries on the continent have been struggling to vaccinate people as quickly as Britain, Israel, the U.S. and elsewhere, and it was long hoped that the AstraZeneca shot would help speed things up. Who will get it?The EMA said Friday that it was recommending a two-dose regimen of the Oxford vaccine, with the...
    NEW BRUNSWICK, N.J. (CBSNewYork/AP) — Johnson & Johnson’s long-awaited coronavirus vaccine appears to protect against the virus with just one shot, though not as strong as some two-shot rivals. The New Jersey-based company said Friday that in the U.S. and seven other countries, the single-shot vaccine was 66% effective overall at preventing moderate to severe illness, and much more protective — 85% — against the most serious symptoms. There was some geographic variation. The vaccine worked better in the U.S. — 72% effective against moderate to severe COVID-19 – compared to 57% in South Africa, where it was up against an easier-to-spread mutated virus. “Gambling on one dose was certainly worthwhile,” Dr. Mathai Mammen, global research chief for J&J’s Janssen Pharmaceutical unit, told The Associated Press. MORE: Potential Johnson & Johnson COVID-19 Vaccine Has Advantages Over Moderna, Pfizer With vaccinations off to a rocky start globally, experts had been counting on...
    Johnson & Johnson’s long-awaited vaccine appears to protect against COVID-19 with just one shot – not as strong as some two-shot rivals but still potentially helpful for a world in dire need of more doses. J&J said Friday that in the U.S. and seven other countries, the single-shot vaccine was 66% effective overall at preventing moderate to severe illness, and much more protective — 85% — against the most serious symptoms. There was some geographic variation. The vaccine worked better in the U.S. — 72% effective against moderate to severe COVID-19 – compared to 57% in South Africa, where it was up against an easier-to-spread mutated virus. “Gambling on one dose was certainly worthwhile,” Dr. Mathai Mammen, global research chief for J&J’s Janssen Pharmaceutical unit, told The Associated Press. With vaccinations off to a rocky start globally, experts had been counting on a one-dose vaccine that would stretch scarce supplies...
    Johnson & Johnson's long-awaited vaccine appears to protect against COVID-19 with just one shot — not as strong as some two-shot rivals but still potentially helpful for a world in dire need of more doses. J&J said Friday that in the U.S. and seven other countries, the single-shot vaccine was 66% effective overall at preventing moderate to severe illness, and much more protective — 85% — against the most serious symptoms.   There was some geographic variation. The vaccine worked better in the U.S. - 72% effective against moderate to severe COVID-19 – compared to 57% in South Africa, where it was up against an easier-to-spread mutated virus. Novavax offers 1st hopeful COVID vaccine trial data on variants "Gambling on one dose was certainly worthwhile," Dr. Mathai Mammen, global research chief for J&J's Janssen Pharmaceutical unit, told The Associated Press.   With vaccinations off to a rocky start globally,...
    Opinion: What it was like trying to get my elderly parents a Covid-19 vaccine 11 soldiers injured after ingesting unknown substance in training J&J Vaccine Is 100% Effective at Stopping Deaths, Hospital Stays (Bloomberg) -- Johnson & Johnson’s one-shot vaccine generated strong protection against Covid-19 in a large, late-stage trial, raising hopes that it can rapidly reshape a stumbling immunization campaign. © Photographer: Scott Eells/Bloomberg The Johnson & Johnson logo is arranged for a photograph in New York, U.S. In the more than 44,000-person study, the vaccine prevented 66% of moderate to severe cases of Covid-19, according to a company statement on Friday. And it was particularly effective at stopping severe disease, preventing 85% of severe infections and 100% of hospitalizations and deaths. “If you can prevent severe disease in a high percentage of individuals, that will alleviate so much of the stress and human suffering” of the pandemic,...
    BALTIMORE (AP/WJZ) — Johnson & Johnson’s long-awaited vaccine appears to protect against COVID-19 with just one shot – not as strong as some two-shot rivals but still potentially helpful for a world in dire need of more doses. J&J said Friday that in the U.S. and seven other countries, the single-shot vaccine was 66% effective overall at preventing moderate to severe illness, and much more protective — 85% — against the most serious symptoms. There was some geographic variation. The vaccine worked better in the U.S. — 72% effective against moderate to severe COVID-19 – compared to 57% in South Africa, where it was up against an easier-to-spread mutated virus. “Gambling on one dose was certainly worthwhile,” Dr. Mathai Mammen, global research chief for J&J’s Janssen Pharmaceutical unit, told The Associated Press. With vaccinations off to a rocky start globally, experts had been counting on a one-dose vaccine that would...
    A single shot of the Johnson and Johnson COVID-19 vaccine can prevent 85 percent of severe cases of the disease, the company announced today. Overall, it is 66 percent effective against both moderate and severe cases of disease. “We’re 85 perfect effective at preventing severe disease, which we define as disease that makes you feel particularly sick at home, or may go to the hospital, or worse,” Mathai Mammen, global head of research and development at Johnson and Johnson, told CNN. The company plans to file for emergency authorization next week. The efficacy is lower than that of the two COVID-19 vaccines already authorized for use in the United States, which prevent about 95 percent of symptomatic cases of COVID-19. Those vaccines each require two doses. Johnson and Johnson ran its trial in the United States, Latin America, and South Africa. In the United States, the vaccine was...
    Johnson & Johnson's one-shot COVID-19 vaccine is more effective in the United States than in other parts of the world, the company said. The vaccine was 72% effective in the U.S., but that percentage dropped in Latin America to 66% and in South Africa to 57%, 28 days post-vaccination, the company announced Friday. Overall, the vaccine was 66% effective in preventing moderate to severe COVID-19, 28 days after vaccination, Johnson & Johnson said. “Johnson & Johnson embarked on the global effort to combat the COVID-19 pandemic a year ago, and has brought the full force of our capabilities, as well as tremendous public-private partnerships, to enable the development of a single-shot vaccine. Our goal all along has been to create a simple, effective solution for the largest number of people possible, and to have maximum impact to help end the pandemic,” said Alex Gorsky, board of directors chairman and...
    Johnson & Johnson's long-awaited vaccine appears to protect against COVID-19 with just one shot – not as strong as some two-shot rivals but still potentially helpful for a world in dire need of more doses. J&J said Friday that in the U.S. and seven other countries, the single-shot vaccine was 66% effective overall at preventing moderate to severe illness, and much more protective - 85% - against the most serious symptoms.   There was some geographic variation. The vaccine worked better in the U.S. - 72% effective against moderate to severe COVID-19 – compared to 57% in South Africa, where it was up against an easier-to-spread mutated virus. Novavax offers 1st hopeful COVID vaccine trial data on variants "Gambling on one dose was certainly worthwhile," Dr. Mathai Mammen, global research chief for J&J's Janssen Pharmaceutical unit, told The Associated Press.   With vaccinations off to a rocky start globally,...
    BOSTON (CBS/AP) – Johnson & Johnson’s long-awaited vaccine appears to protect against COVID-19 with just one shot – not as strong as some two-shot rivals but still potentially helpful for a world in dire need of more doses. J&J said Friday that in the U.S. and seven other countries, the single-shot vaccine was 66% effective overall at preventing moderate to severe illness, and much more protective — 85% — against the most serious symptoms. There was some geographic variation. The vaccine worked better in the U.S. — 72% effective against moderate to severe COVID-19 – compared to 57% in South Africa, where it was up against an easier-to-spread mutated virus. “Gambling on one dose was certainly worthwhile,” Dr. Mathai Mammen, global research chief for J&J’s Janssen Pharmaceutical unit, told The Associated Press. Johnson & Johnson developed the vaccine with Beth Israel Deaconess Medical Center in Boston. With vaccinations off to...
    Johnson & Johnson on Friday said its single-shot coronavirus vaccine was 72% effective in preventing moderate-to-severe COVID-19 in the U.S, but fell to 66% in a larger trial conducted worldwide. The results stem from a Phase 3 ENSEMBLE clinical trial, which involved 43,783 participants. The shot was found to be 66% effective in preventing mild-to-moderate illness in Latin America, and 57% effective in South Africa at 28 days post-vaccination. J&J’s vaccine differs from currently approved jabs in the U.S. in that it requires a single shot as opposed to two doses, and was created using an adenovirus rather than mRNA technology. "Johnson & Johnson embarked on the global effort to combat the COVID-19 pandemic a year ago, and has brought the full force of our capabilities, as well as tremendous public-private partnerships, to enable the development of a single-shot vaccine. Our goal all along has been to create a simple,...
    (AP)– Johnson & Johnson’s long-awaited vaccine appears to protect against COVID-19 with just one shot – not as strong as some two-shot rivals but still potentially helpful for a world in dire need of more doses. J&J said Friday that in the U.S. and seven other countries, the single-shot vaccine was 66% effective overall at preventing moderate to severe illness, and much more protective — 85% — against the most serious symptoms. There was some geographic variation. The vaccine worked better in the U.S. — 72% effective against moderate to severe COVID-19 – compared to 57% in South Africa, where it was up against an easier-to-spread mutated virus. “Gambling on one dose was certainly worthwhile,” Dr. Mathai Mammen, global research chief for J&J’s Janssen Pharmaceutical unit, told The Associated Press. With vaccinations off to a rocky start globally, experts had been counting on a one-dose vaccine that would stretch scarce supplies...
    NEW BRUNSWICK, N.J. -- Johnson & Johnson COVID-19 vaccine is 85% effective against severe forms of the disease, according to its phase 3 trial data released Friday.Food and Drug Administration approval of the Johnson & Johnson will significantly boost the nation's COVID-19 vaccine supply following months of bumpy rollout.The two vaccines authorized in the U.S so far, from Pfizer and Moderna, each require two doses, several weeks apart, for optimal effectiveness. Johnson & Johnson's, however, is single dose, and experts say this will make it easier for managing vaccination efforts.Pfizer and Moderna's vaccines are made by using a piece of genetic code called mRNA.Making small amounts of mRNA in a research lab is easy but "prior to this, nobody made a billion doses or 100 million or even a million doses of mRNA," said Dr. Drew Weissman of the University of Pennsylvania, who helped pioneer mRNA technology.J&J's are made with...
    Johnson & Johnson Coronavirus vaccine illustrationDado Ruvic | Reuters Johnson & Johnson said Friday that its one-dose coronavirus vaccine was 72% effective in protecting against Covid-19 in the United States. The vaccine, however, was less potent in other regions, it said. The highly anticipated results were based on 468 confirmed Covid-19 infections among the phase three trial's more than 43,000 volunteers, according to J&J. The company said the trial includes those infected with B.1.351, the new, highly contagious strain found in South Africa. The level of protection varied by region, J&J said, with the vaccine demonstrating 66% effectiveness overall, 72% in the United States, 66% in Latin America and 57% in South Africa after four weeks. "We're proud to have reached this critical milestone and our commitment to address this global health crisis continues with urgency for everyone, everywhere," J&J CEO Alex Gorsky said in a statement. J&J said the...
    Doctors are recommending that people not take over-the-counter pain medications before receiving a coronavirus vaccine. Both the Moderna and Pfizer-BioNTech shots have been known to cause side effects such as pain at the site of injection, headaches, fever, chills and fatigue. Because of this some people may try to prevent them by taking pain relievers like ibuprofen (Motrin and Advil) or acetaminophen (Tylenol) in advance. Now, infectious disease specialists tell ABC News the medications may dampen the immune system and prevent the production of antibodies, therefore dulling the effectiveness of the vaccine.  Infectious disease specialists are warning people against taking ibuprofen like Advil (left) or acetaminophen like Tylenol (right) as a prophylactic against coronavirus vaccine side effects such as pain at the site of injection, headaches and fever Pain relievers may suppress parts of the immune system and inhibit antibody production, therefore reducing the vaccine's effectiveness 'We do...
    UC Berkeley University Health Services medical assistant Nova Rodriguez prepares a dose of the Moderna COVID-19 vaccine before administering it to fellow University Health Services staff at Tang Center near UC Berkeley in Berkeley, Calif.Jessica Christian | San Francisco Chronicle | Hearst Newspapers via Getty Images Moderna said Monday it's accelerating work on a Covid-19 booster shot to guard against the recently discovered variant in South Africa. Its researchers said its current coronavirus vaccine appears to work against the two highly transmissible strains found in the U.K. and South Africa, although it looks like it may be less effective against the latter. The two-dose vaccine produced an antibody response against multiple variants, including B.1.1.7 and B.1.351, which were first identified in the U.K. and South Africa, respectively, according to a Moderna study conducted in collaboration with the National Institute of Allergy and Infectious Diseases. The study has not yet...
    A single dose of Pfizer’s vaccine may be less effective than the drugmaker had indicated, Israel’s COVID-19 czar has warned. Nachman Ash — Israel’s equivalent to Dr. Anthony Fauci — said that the protection offered by the first dose is “less effective than we had thought,” Army Radio reported. “Many people have been infected between the first and second injections of the vaccine,” Ash said, adding that the protective effect appears “lower than [the data] presented by Pfizer.” The pharmaceutical giant has claimed that trials show that it is roughly 52 percent effective around 12 days after receiving the first shot, the BBC reported . But that level of protection rises to 95 percent after around two weeks after the second dose. It’s unclear exactly how effective the shot has been for the more than 2 million Israelis who have already received the first dose. Questions were raised about the vaccine’s performance...
    Dr. Anthony Fauci on Sunday that Johnson & Johnson and AstraZeneca could send studies of their COVID-19 vaccines to the feds for approval within “weeks.” “I would imagine within a period of a week or so, or at the most, a couple of weeks — they’re going to be getting their data together and showing it to the FDA,” the director of the National Institute of Allergy and Infectious Diseases said on “Meet the Press.” “And, they’re going to have to get their data and safety monitoring board to look at it to see if it is appropriate to start, you know, essentially putting the package together to get an emergency use authorization. But we’re weeks away, not months away, for sure.” If the data shows the shots are safe and effective, the vaccines would be the third and fourth to seek emergency use authorization in the nation. The...
    Full data shows China’s Sinovac vaccine candidate, “CoronaVac,” to be 50.38 percent effective against the Chinese coronavirus in late-stage trials, Brazilian state researchers revealed Tuesday, according to the Wall Street Journal. The figure is nearly 30 percentage points lower than the 78 percent efficacy rate for CoronaVac which the São Paulo state government-funded Butantan Institute previously announced on January 7. Butantan is currently running final-stage clinical trials for CoronaVac, a Chinese coronavirus vaccine candidate developed by China’s Sinovac Biotech. The institute submitted new data to Brazil’s federal health regulator at a press conference on January 12, listing CoronaVac’s efficacy rate as just under 50.4 percent. CoronaVac’s previous efficacy rate of 78 percent “only included volunteers who suffered mild to severe cases” of the Chinese coronavirus, Butantan said Tuesday, according to the Wall Street Journal. “When data from all volunteers is considered, including those who contracted ‘very mild’ cases of Covid-19 [Chinese coronavirus] and required...
    US sets Covid death record as researchers point to asymptomatic cases as major source Woman accused of attacking teen in NY hotel arrested after fleeing police Sinovac Shot Shown 78% Effective in Brazil After Data Confusion (Bloomberg) -- The vaccine developed by China’s Sinovac Biotech Ltd. was found to be 78% effective against Covid-19 in late-stage trials in Brazil, the most definitive evidence so far on the shot’s efficacy after previous data sparked doubt and confusion. Load Error The protection rate, confirmed by Sao Paulo state officials, was derived from Sinovac’s most advanced final-phase trials in Brazil involving about 13,000 participants. Coming after data was withheld at a progress update in late December, the rate is still below the roughly 95% effectiveness seen in cutting-edge mRNA vaccines developed by Pfizer Inc. and Moderna Inc. and being deployed in the U.S. Sinovac’s CoronaVac vaccine was 78% effective...
    Three new studies suggest that as many people as possible should receive at least one dose of the coronavirus vaccine.  Currently, both vaccines approved for emergency use authorization in the U.S. - from Pfizer Inc and Moderna Inc - require two doses administered about one month apart. But researchers from Yale University, Stanford University and the University of Washington have found that an initial dose is about 50 percent effective at preventing COVID-19 infection. This could help curb the spread of the virus and help relieve hospital systems from some of the strain they are under - and then second doses could be given a few months later.  It comes as the new threat of 'super-covid' variants arises in the U.S., where at least 10 people have the variation that has triggered a third wave of lockdowns in the UK.  The new strain, known as B 1.1.1.7., has been identified in...
    Black man in New Jersey misidentified by facial recognition tech and falsely jailed, lawsuit claims The girlfriend of suspected Nashville bomber Anthony Quinn Warner reportedly told police he was building a bomb more than a year ago Sinopharm Says Shot 79% Effective and Seeks General Use in China (Bloomberg) -- State-backed vaccine developer China National Biotec Group Co. said one of its shots is effective in preventing Covid-19 in 79.3% of people, allowing it to apply for authorization to market the inoculation for use in the general population. © Getty Images via Bloomberg A health worker in Peru prepares a syringe to inoculate a volunteer with the Sinopharm vaccine on Dec. 9. The interim data shows the vaccine, which is already authorized for emergency use in China, is safe and people who took the shots in the trial all generated high levels of antibodies, according to a statement posted...
    Novavax will begin final-stage trial of its COVID-19 vaccine candidate, enrolling around 30,000 participants in the US and Mexico, federal health officials said. The Maryland-based company will test the shot, known as NVX-CoV2373. at 115 sites, according to the National Institute of Allergy and Infectious Diseases. “The launch of this study — the fifth investigational COVID-19 vaccine candidate to be tested in a Phase 3 trial in the United States — demonstrates our resolve to end the pandemic through development of multiple safe and effective vaccines,” Dr. Anthony Fauci, who is director of the agency, said in a statement Monday. The vaccine maker is already carrying out Phase 3 trials in the United Kingdom, where enrollment was completed last month. Novavax CEO Stan Erck said the UK trials will show whether the vaccine is as effective as the others already on the market in the US. “We don’t know until...
    Coronavirus updates: Air travel hits record high amid winter holidays Ossoff, Warnock warn of dwindling funds; Schumer pessimistic on Democrats chances, source says Novavax Begins U.S. Phase 3 Trial of Coronavirus Vaccine (Bloomberg) -- Novavax Inc. will start the final-stage trial of its Covid-19 vaccine with 30,000 people in the U.S. and Mexico, opening another avenue for shots to fight the pandemic, the National Institute of Allergy and Infectious Diseases said. © Bloomberg Signage is displayed outside the Novavax Inc. headquarters in Gaithersburg, Maryland, U.S., on Saturday, Aug. 8, 2020. Novavax shares last week touched a five-year high as investors assessed early data on its experimental vaccine for Covid-19. The trial, to be completed across 115 locations, is the latest large-scale effort in the U.S. to evaluate vaccines to protect against the virus that’s killed more than 330,000 Americans. The company is also studying the vaccine in a large...
    LONDON (AP) — The head of drugmaker AstraZeneca, which is developing a coronavirus vaccine widely expected to be approved by U.K. authorities this week, said Sunday that researchers believe the shot will be effective against a new variant of the virus driving a rapid surge in infections in Britain. AstraZeneca chief executive Pascal Soriot also told the Sunday Times that researchers developing its vaccine have figured out a “winning formula” making the jab as effective as rival candidates. Some have raised concern that the AstraZeneca vaccine, which is being developed with Oxford University, may not be as good as the one made by Pfizer already being distributed in the U.K. and other countries. Partial results suggest that the AstraZeneca shot is about 70% effective for preventing illness from coronavirus infection, compared to the 95% efficacy reported by Pfizer and its German partner BioNTech. “We think we have figured out the...
    LONDON (AP) — The head of drugmaker AstraZeneca, which is developing a coronavirus vaccine widely expected to be approved by U.K. authorities this week, said Sunday that researchers believe the shot will be effective against a new variant of the virus driving a rapid surge in infections in Britain. AstraZeneca chief executive Pascal Soriot also told the Sunday Times that researchers developing its vaccine have figured out a “winning formula” making the jab as effective as rival candidates. Some have raised concern that the AstraZeneca vaccine, which is being developed with Oxford University, may not be as good as the one made by Pfizer already being distributed in the U.K. and other countries. Partial results suggest that the AstraZeneca shot is about 70% effective for preventing illness from coronavirus infection, compared to the 95% efficacy reported by Pfizer and its German partner BioNTech. “We think we have figured out...
    Bodycam footage in shooting of Black man shows police apparently not render aid Dr Anthony Fauci turns 80 – and even his birthday surprise obeyed Covid rules Sinovac Covid Shot More Than 50% Effective, But Data Withheld (Bloomberg) -- A Covid-19 vaccine developed by Chinese pharmaceutical firm Sinovac Biotech Ltd. was found to be more than 50% effective in a Brazilian clinical trial, though researchers delayed releasing more information at the request of the company. © Photographer: Lintao Zhang/Getty Images AsiaPac BEIJING, CHINA - SEPTEMBER 05: A booth displaying China's Sinovac Biotech Ltd. shows a COVID-19 vaccine candidate during the 2020 China International Fair for Trade in Services (CIFTIS) at Beijing Olympic Park on September 5, 2020 in Beijing, China. As China recovers from the COVID-19 epidemic, about 2,000 Chinese and foreign enterprises will participate and showcase their newest technology in public health and digital technology in the China...
    The FDA has released its briefing document for Moderna’s COVID-19 vaccine, and it looks pretty great: This looks even better than the Pfizer vaccine, and it has the added advantage of requiring only normal refrigeration for storage, rather than the super-cold refrigeration required by Pfizer’s product. As with the Pfizer vaccine, patients reported a fairly normal incidence of minor side-effects, including headache, fever, fatigue, muscle aches, joint pain, chills, and pain at the injection site. There were apparently no serious side effects. The Moderna product is a two-shot vaccine, with the second shot given 28 days after the first—although the chart suggests that it’s pretty effective even after the first dose. Like the Pfizer vaccine, it appears to become effective about ten days after the first injection. One other thing of note. This might be simply a coincidence, but every single person in the vaccine group who contracted COVID-19...
    DUBAI, United Arab Emirates (AP) — Bahrain said Sunday it approved the use of a Chinese coronavirus vaccine, following its earlier approval of a vaccine made by Pfizer and its German partner BioNTech. Separately, Kuwait has granted emergency use for the Pfizer vaccine. Bahrain’s state-run news agency said the Sinopharm vaccine would be available in the island kingdom off the coast of Saudi Arabia in the Persian Gulf. It offered few details though on study results of the vaccine, in line with the United Arab Emirates, which last week announced the vaccine was 86% effective. The Emirati statement provided few details but marked the first public release of information on the efficacy of the shot. Bahrain said over 7,700 signed up to take part in a trial of the Sinopharm vaccine in the kingdom. The kingdom earlier said it plans to give the public free coronavirus vaccines, but has yet...
    Hallelujah.  The Food and Drug Administration approved the emergency use of Pfizer’s COVID-19 vaccine Friday as a second wave of the coronavirus continues to batter a pandemic-weary nation, the New York Times reported Friday night. The approval comes after a government advisory panel backed the use of the vaccine, which paved the way for the FDA to grant its green light.  In a 17-4 vote with one abstention Thursday, the FDA’s Vaccines and Related Biological Products Advisory Committee concluded that the shot appears safe and effective for emergency use in people 16 and older.  Earlier Friday, Health and Human Services Secretary Alex Azar hinted approval was right around the corner and said people could be receiving the shot as early as Monday or Tuesday.  “I’ve got some good news for you,” Azar said on ABC’s “Good Morning America.” “Just a little bit ago, the FDA informed Pfizer that they...
    CAIRO (AP) — Egypt on Thursday received its first shipment of a Chinese coronavirus vaccine, which was tested in the United Arab Emirates and is said to be 86% effective. The shipment by Chinese state-owned pharmaceutical giant Sinopharm landed at Cairo’s international airport from the UAE. Cairo and Abu Dhabi are close allies. Egyptian Health Minister Hala Zayed and diplomats from China and the UAE were at the airport to greet the shipment. Health ministry spokesman Khaled Megahed said in a statement that the government would first vaccinate health care workers, particularly those who deal with COVID-19 cases. He said they would receive two doses of the vaccine over 21 days. Egypt, the Arab world’s most populous country, has seen an increase in confirmed coronavirus infections in recent weeks amid warnings by the government about a second wave of the pandemic. Egypt reported 445 newly confirmed coronavirus infections Thursday and...
    ABU DHABI, United Arab Emirates -- The United Arab Emirates said Wednesday a Chinese coronavirus vaccine tested in the federation of sheikhdoms is 86% effective, in a statement that provided few details but marked the first public release of information on the efficacy of the shot.The announcement brought yet another shot into the worldwide race for a vaccine to end the pandemic, a scientific effort that has seen China and Russia compete with Western firms for an effective inoculation. While questions remain about the Sinopharm shot, already at least one country outside China plans to roll it out in a mass-vaccination campaign.The UAE, home to Dubai and Abu Dhabi, conducted a trial beginning in September of the vaccine by Chinese state-owned pharmaceutical giant Sinopharm involving 31,000 volunteers from 125 nations. Volunteers between 18 and 60 years old received two doses of the vaccine over 28 days.The UAE's Health and Prevention...
    The Pfizer-BioNTech coronavirus vaccine is both safe and effective, according to the U.S. Food and Drug Administration. In a report released Tuesday morning, the FDA indicated that it could greenlight the country’s first Covid-19 inoculation within days.  If Pfizer’s shot is granted an emergency use authorization, or EUA, the immunizations — which are administered in two doses about three weeks apart — could start as soon as next week. Many people are now wondering whether this will be just like getting the flu vaccine.  The short answer is: No, not really. One Pfizer trial participant told CNBC that after the second shot, he woke up with chills, shaking so hard he cracked a tooth. "It hurt to even just lay in my bed sheet," he said.  Others experienced headaches and fatigue. The FDA said that while side effects of the Pfizer vaccine are common, there are “no specific safety concerns...
    The coronavirus vaccine made by Pfizer Inc. and its German partner BioNTech SE is highly effective in preventing COVID-19 and there are no safety concerns that would prevent it from being granted an emergency-use authorization, according to a report by staff of the U.S. Food and Drug Administration. The report offers a first look at the U.S. review of the vaccine ahead of a public meeting Thursday of outside advisers to the agency. The FDA could clear the shot shortly after the meeting, with as many as 6.4 million doses immediately available to kick off a vast immunization effort designed to end a pandemic that has killed more than 283,000 Americans. The findings, posted on the agency’s website Tuesday, echoed previously disclosed data from the companies that showed the vaccine was 95% effective in preventing symptomatic COVID-19. It also said that two months of trial data revealed no significant safety...
    $15K fine for NYC synagogue with 7,000 person capacity after massive secret wedding Mexico moves to stem unauthorized sharing of sexual images Moderna Soars to Record Ahead of Final Covid Vaccine Analysis (Bloomberg) -- Moderna Inc. climbed as much as 10% hitting a record high on Wednesday while investors await the final analysis of its Covid-19 shots. That final look at the data is expected within days after 151 volunteers in the 30,000 person study develop symptoms of the virus. It would be the final step before the biotech company files for an emergency use authorization. Moderna is poised to be the second company to do so in the U.S. after Pfizer Inc. was the first to file with U.S. regulators on Friday. Pfizer and German partner BioNTech SE’s shot will face a Food and Drug Administration panel on Dec. 10. © Bloomberg Moderna stock surges with final analysis...
    Moderna’s coronavirus vaccine may not get life back to normal right away because it hasn’t yet been proven to prevent the deadly bug from spreading, the company’s top doctor says. Research has shown that the biotech firm’s shot is effective at preventing people from getting sick with COVID-19, but there’s no hard evidence that it stops them from carrying the virus “transiently” and potentially infecting others who haven’t been vaccinated, according to Dr. Tal Zaks, Moderna’s chief medical officer. “I think we need to be careful, as we get vaccinated, not to over-interpret the results,” Zaks told Axios in a TV interview released Monday. “When we start the deployment of this vaccine, we will not have sufficient concrete data to prove that this vaccine reduces transmission.” “Do I believe that it reduces transmission? Absolutely yes, and I say this because of the science,” he added. “But absent proof, I think...
            by Linda A. Johnson and Frank Jordans  Pfizer said Wednesday that new test results show its coronavirus vaccine is 95% effective, is safe and also protects older people most at risk of dying — the last data needed to seek emergency use of limited shot supplies as the catastrophic outbreak worsens across the globe. The announcement from Pfizer and its German partner BioNTech, just a week after they revealed the first promising preliminary results, comes as the team is preparing within days to formally ask U.S. regulators to allow emergency use of the vaccine. In this Nov. 9, 2020, file photo, pedestrians walk past Pfizer world headquarters in New York. Pfizer announced Wednesday, Nov. 18, 2020, more results in its ongoing coronavirus vaccine study that suggest the shots are 95% effective a month after the first dose. (AP Photo/Bebeto Matthews, File) They also have begun “rolling...
    Loading the player... Pfizer said Wednesday that new test results show its coronavirus vaccine is 95% effective, is safe and also protects older people most at risk of dying — the last data needed to seek emergency use of limited shot supplies as the catastrophic outbreak worsens across the globe. The announcement from Pfizer and its German partner BioNTech, just a week after they revealed the first promising preliminary results, comes as the team is preparing within days to formally ask U.S. regulators to allow emergency use of the vaccine. Read More: Pfizer launches trial vaccine delivery program in four states They also have begun “rolling submissions” for the vaccine with regulators in Europe, the U.K. and Canada and soon will add this new data. Pfizer and BioNTech had initially estimated the vaccine was more than 90% effective after 94 infections had been counted in a study that included 44,000...
    By LINDA A. JOHNSON, AP Medical Writer Pfizer says that more interim results from its ongoing coronavirus vaccine study suggest the shots are 95% effective and that the vaccine protects older people most at risk of dying from COVID-19. The announcement, just a week after Pfizer first revealed promising preliminary results, comes as the company is preparing within days to formally ask U.S. regulators to allow emergency use of the vaccine. Pfizer initially had estimated its vaccine, developed with German partner BioNTech, was more than 90% effective after 94 infections had been counted. With Wednesday’s announcement, the company now has accumulated 170 infections in the study -- and said only eight of them occurred in volunteers who got the actual vaccine rather than a dummy shot. One of those eight developed severe disease, the company said. The company has not yet released detailed data on its study, and results have...
    Pfizer says that more interim results from its ongoing coronavirus vaccine study suggest the shots are 95% effective and that the vaccine protects older people most at risk of dying from COVID-19.The announcement, just a week after Pfizer first revealed promising preliminary results, comes as the company is preparing within days to formally ask U.S. regulators to allow emergency use of the vaccine.Pfizer initially had estimated its vaccine, developed with German partner BioNTech, was more than 90% effective after 94 infections had been counted. With Wednesday's announcement, the company now has accumulated 170 infections in the study -- and said only eight of them occurred in volunteers who got the actual vaccine rather than a dummy shot. One of those eight developed severe disease, the company said.The company has not yet released detailed data on its study, and results have not been analyzed by independent experts.Pfizer said its vaccine was...
12